Key Drivers
- Margin Expansion
- Strong Liquidity
- Rising Leverage
AIAI Summary
ADMA's low valuation is attractive only if ASCENIV growth reflects genuine end-market demand rather than distributor inventory build; investors should wait for evidence of inventory sell-through and receivables collection before underwriting a re-rating, as litigation and governance risks could otherwise expose overstated earnings quality.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Liquidity
- •Rising Leverage
ADMA offers strong profitability, expanding margins, liquidity, and cheaper valuation, but rising debt, elevated working capital, and negative retained earnings warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Recent rebound
- •Resistance overhead
- •Support fragile
ADMA remains in a short-term downtrend despite rebounding from $8.61 to $9.11, with upside confirmation requiring a break above $9.62 and downside risk rising below $8.90.
Rebound from $8.61 to $9.11 suggests buyers defended the recent low
Sentiment & News
Key News Insights:
- •Securities lawsuit
- •Channel-stuffing claims
- •Share price weakness
ADMA faces mounting legal scrutiny over alleged channel-stuffing and fiduciary breaches, pressuring investor sentiment and shares.
Ongoing investigations and negative sentiment could sustain downside pressure on ADMA shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings